SK pharmteco Receives FDA NAI Status for La Porte, Texas Facility

RANCHO CORDOVA, Calif. – March 17, 2026 – SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced the successful completion of a regulatory inspection by the U.S. Food and Drug Administration (FDA) of its compact molecule manufacturing facility in La Porte, Texas. The inspection, conducted from February 9 to February 12, 2026, resulted in a “No Action Indicated” (NAI) status, signifying full compliance with the highest regulatory standards.

FDA Inspection Details

The FDA’s general inspection encompassed thorough evaluations of the facility’s warehouse, manufacturing plant, and analytical laboratories. Inspectors meticulously reviewed the site’s quality systems and manufacturing operations, including batch records, Corrective and Preventive Actions (CAPAs), deviation and Out-of-Specification (OOS) investigations, and change controls. The agency similarly verified the integrity of equipment qualifications, purified water systems, and process and cleaning validations.

Commitment to Quality and Continuous Improvement

“The successful completion of this FDA inspection directly reflects the commitment to excellence and strong quality culture of our La Porte team,” said Kalen Minvielle, Head of Small Molecule, North America. “Maintaining an NAI status is a significant achievement that continues to highlight the strength of our systems and disciplined approach to building quality into every step of the process. It ensures our customers can continue to rely on SK pharmteco for secure, compliant, and uninterrupted manufacturing of life-enhancing medicines.”

SK pharmteco actively collaborates with the FDA in pursuit of continuous improvement, recently participating in the FDA Quality Management Maturity (QMM) program. This initiative recognizes drug manufacturers demonstrating advancements beyond standard compliance and fostering a culture of reliability.

About SK pharmteco

SK pharmteco is a global CDMO with a network of production sites, research and development facilities, and analytical laboratories across the United States, Europe, and South Korea. The company specializes in small molecules, peptides, and viral vectors, offering comprehensive development and manufacturing solutions to biopharmaceutical partners worldwide. SK pharmteco is a subsidiary of SK Inc., a strategic investment company and part of SK Group, South Korea’s second-largest conglomerate.

Contact:
Keith Bowermaster, APR, CCMP
Consultant en communication
keith.bowermaster@skpt.com